How have CLVLY shares performed in 2024?

Clinuvel Pharmaceuticals' stock was trading at $11.0550 at the start of the year. Since then, CLVLY shares have decreased by 8.7% and is now trading at $10.09. View the best growth stocks for 2024 here .

Are investors shorting Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,900 shares, an increase of 680.0% from the March 15th total of 500 shares. Based on an average trading volume of 5,300 shares, the days-to-cover ratio is presently 0.7 days. View Clinuvel Pharmaceuticals' Short Interest .

How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals announced a dividend on Wednesday, August 30th. Stockholders of record on Friday, September 8th will be given a dividend of $0.0283 per share on Monday, October 2nd. The ex-dividend date is Thursday, September 7th. This is a boost from the stock's previous dividend of $0.02. Read our dividend analysis for CLVLY .

How do I buy shares of Clinuvel Pharmaceuticals?

Shares of CLVLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CLVLY

Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)

Free CLVLY Stock Alerts

$10.09

+0.31 (+3.17%)

(As of 04/15/2024 ET)

Compare

Today's Range: $9.75
▼
$10.09
50-Day Range: $8.54
▼
$10.70
52-Week Range: $8.54
▼
$13.92

Volume: 1,175 shs
Average Volume: 4,122 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Dividend Financials Headlines SEC Filings Short Interest

Get Clinuvel Pharmaceuticals alerts:

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Clinuvel Pharmaceuticals Stock (OTCMKTS:CLVLY)

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

CLVLY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLVLY Stock News Headlines

March 28, 2024 | globenewswire.com

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

March 21, 2024 | finance.yahoo.com

Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years ago

April 15, 2024 | Insiders Exposed (Ad)

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

March 20, 2024 | investing.com

Clinuvel Pharmaceuticals Ltd ADR (CLVLY)

March 9, 2024 | fool.com.au

The Clinuvel Pharmaceuticals share price is up 236% in 12 months

March 4, 2024 | globenewswire.com

Malibu shines a light on CLINUVEL's pioneering work in photomedicine

March 2, 2024 | wsj.com

Clinuvel Pharmaceuticals Ltd. ADR

February 25, 2024 | msn.com

Clinuvel Pharmaceuticals (CLVLF) Price Target Increased by 5.58% to 19.75

April 15, 2024 | Insiders Exposed (Ad)

This consistently signaled gains of 453%... 610%... and even 1036%...

February 23, 2024 | msn.com

Clinuvel Pharmaceuticals GAAP EPS of A$0.22, revenue of A$32.25B

January 30, 2024 | wsj.com

Clinuvel Pharmaceuticals Ltd.

December 9, 2023 | morningstar.com

Clinuvel Pharmaceuticals Ltd ADR

December 2, 2023 | morningstar.com

Clinuvel Pharmaceuticals Ltd ADR CLVLY

October 31, 2023 | nasdaq.com

Clinuvel Pharmaceuticals Ltd - ADR (CLVLY) Price Target Increased by 18.27% to 21.08

October 5, 2023 | finance.yahoo.com

Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 38% loss from investing in the stock three years ago

September 1, 2023 | msn.com

Clinuvel Pharmaceuticals (CLVLF) Price Target Increased by 12.19% to 18.70

May 3, 2023 | finance.yahoo.com

Could The Market Be Wrong About Clinuvel Pharmaceuticals Limited (ASX:CUV) Given Its Attractive Financial Prospects?

May 1, 2023 | msn.com

Some Patients With a Rare Disease Face Hurdles Getting the Only Treatment

March 30, 2023 | finance.yahoo.com

Clinuvel Pharmaceuticals (ASX:CUV) shareholders have earned a 14% CAGR over the last five years

March 1, 2023 | finance.yahoo.com

Analysts Just Slashed Their Clinuvel Pharmaceuticals Limited (ASX:CUV) EPS Numbers

March 1, 2023 | finance.yahoo.com

CLINUVEL Launches CYACÊLLE, Next Generation Solar Care

February 25, 2023 | msn.com

Why Clinuvel, Cogstate, Omni Bridgeway, and Westgold shares are sinking

February 24, 2023 | finance.yahoo.com

Clinuvel Pharmaceuticals First Half 2023 Earnings: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)

February 24, 2023 | finanznachrichten.de

Clinuvel Pharmaceuticals Limited: Global SCENESSE demand drives increased CLINUVEL revenues, earnings

February 23, 2023 | finance.yahoo.com

Global SCENESSE® demand drives increased CLINUVEL revenues, earnings

February 2, 2023 | finanznachrichten.de

Clinuvel Pharmaceuticals Limited: CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

January 15, 2023 | finance.yahoo.com

CLINUVEL Trial Results Show Drug Reduces DNA Damage

See More Headlines

Receive CLVLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:CLVLY
CUSIP: N/A
CIK: 1290877
Web: www.clinuvel.com
Phone: (139) 660-4900
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Philippe Jacques Wolgen M.B.A. (Age 61)
M.D., CEO, MD & Director
Comp: $1.81M
Mr. Darren Michael Keamy B.Com. (Age 51)
CPA, CFO & Company Secretary
Comp: $270.51k
Dr. Dennis J. Wright
Chief Scientific Officer
Mr. Lachlan Hay
Director of Global Operations
Mr. Malcolm Bull
Head of Australian Operations & Investor Relations
Dr. Rose Quadbeck-Diel
Senior Vice President of Regulatory Affairs
Dr. Azza Hamila
Head of Quality & Drug Safety

Key Competitors

View All Competitors

CLVLY Stock Analysis - Frequently Asked Questions

How have CLVLY shares performed in 2024?: Clinuvel Pharmaceuticals' stock was trading at $11.0550 at the start of the year. Since then, CLVLY shares have decreased by 8.7% and is now trading at $10.09.
View the best growth stocks for 2024 here.
Are investors shorting Clinuvel Pharmaceuticals?: Clinuvel Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,900 shares, an increase of 680.0% from the March 15th total of 500 shares. Based on an average trading volume of 5,300 shares, the days-to-cover ratio is presently 0.7 days.
View Clinuvel Pharmaceuticals' Short Interest.
How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals?: Clinuvel Pharmaceuticals announced a dividend on Wednesday, August 30th. Stockholders of record on Friday, September 8th will be given a dividend of $0.0283 per share on Monday, October 2nd. The ex-dividend date is Thursday, September 7th. This is a boost from the stock's previous dividend of $0.02.
Read our dividend analysis for CLVLY.
How do I buy shares of Clinuvel Pharmaceuticals?: Shares of CLVLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CLVLY) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial